Brainstorm Cell Therapeutics, Inc. (BCLI): Price to Sales
The prospects for the NurOwn platform are limited by strict FDA oversight, which hinders the creation of a sustainable competitive advantage for Brainstorm Cell (BCLI). Risks are further exacerbated by unstable reagent supplies and complexities in protecting foreign patents. Future growth is based on scaling a high-margin cell therapy method. The price-to-sales ratio reflects volatile valuations, while captures the current value of the indicator.
Analytical breakdowns for Brainstorm Cell Therapeutics, Inc. (BCLI)
- stock quotes and analyst forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Brainstorm Cell|BCLI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BrainStorm Cell Therapeutics Inc.|BCLI - Company Aggregate Debts|Debts to Book Value Brainstorm Cell|BCLI - Company Long-Term Debt|Company Short-Term Debt BrainStorm Cell Therapeutics|Quick Liquidity brainstorm-cell.com
- earnings and valuation multiples information:
BCLI - Net Profit|Expected Profit Brainstorm Cell|BCLI - P/E Multiple|Projected Price to Earnings Brainstorm Cell Therapeutics Inc.|BCLI - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Brainstorm Cell|BCLI - Operating profit EBITDA|Net earnings per share for the last four quarters BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months brainstorm-cell.com|BCLI - Earnings growth in current year|Expected net earnings per share growth next year Brainstorm Cell
- total revenue and sales volume data:
General company analysis:BCLI - brainstorm-cell.com
Brainstorm Cell (BCLI) 's struggle for patent superiority in neurodegeneration therapy directly impacts its market capitalization relative to generated revenues. The price-to-sales ratio measures the premium investors are willing to pay for every dollar of sales, reflecting expectations for future expansion. By analyzing the company's P/S monitoring, one can identify critical points for strategy re-evaluation or risks of a deep asset drawdown.
Competitors of Brainstorm Cell
Market Cap to Sales Volume BIIB|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd (RGC) - Price to Sales|AXSM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue vikingtherapeutics.com|Market Cap to Revenue SUPN|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Market Cap to Revenue Harmony Corp HRMY|P/S Multiple BHVN (Biohaven Ltd.)|amylyx.com (AMLX) - Price to Sales|TRVI - Price-to-Revenue Ratio|PRAX: Price-to-Revenue Ratio|Anavex Corp (AVXL) - Price-to-Revenue Ratio|CBLL (CeriBell EEG) - Price-to-Revenue Ratio|PRTA (Prothena Biosciences) - P/S Multiple|Price-to-Revenue Ratio ALEC|P/S Multiple ANNX|Market Cap to Revenue omeros.com OMER|Price-to-Revenue Ratio Neurogene Corp NGNE|AC Immune Inc - Price-to-Revenue Ratio|Voyager Therapeutics - P/S Multiple|Price-to-Revenue Coefficient neumoratx.com NMRA|Scilex (SCLX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TVGN|ACOG (Alpha Cognition Inc) - P/S Multiple|Price to Sales Cognition Therapeutics Inc. CGTX|Market Cap to Revenue IKT (Inhibikase Therapeutics)|P/S Multiple cassavasciences.com (SAVA)|Price-to-Revenue Ratio Assertio ASRT|Market Capitalization-to-Revenue Ratio COYA|VTGN - Price-to-Revenue Ratio|Price to Sales Ovid Therapeutics Inc.|ABOS: P/S Multiple|CRVO (cervomed.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Market Capitalization-to-Revenue Ratio|P/S Multiple PEPG|P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|P/S Multiple RLMD (Relmada Therapeutics)|Price-to-Revenue Coefficient annovisbio.com (ANVS)|GRCE - Price-to-Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Revenue Ratio|anewmeds.com (KLTO) - Price-to-Revenue Ratio|NRSN - Price-to-Revenue Coefficient|Market Cap to Revenue RVPH|MTVA (MetaVia, Inc.) - Market Cap to Sales Volume|Price-to-Revenue Ratio NeurAxis (NRXS)|HSDT - Price to Sales|Price-to-Revenue Ratio Passage Bio PASG|Market Capitalization-to-Revenue Ratio NEUP|NERV - Price-to-Revenue Ratio|athira.com (ATHA) - Market Cap to Revenue|ADXN (Addex Therapeutics Ltd) - Market Cap to Revenue|Alzamend Neuro - Market Capitalization-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|Market Cap to Revenue Protagenic (PTIX)|P/S Multiple KTTA|CRGT - Price to Sales|Price-to-Revenue Ratio Avenue Therapeutics, Inc. ATXI|Cara Therapeutics Inc. - Price-to-Revenue Ratio|CHRO - Price-to-Revenue Ratio|ELYM: Price-to-Revenue Ratio|ITCI: P/S Multiple|LBPH (longboardpharma.com) - Price-to-Revenue Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Market Cap to Revenue NKGen Biotech Inc (NKGN)|Price-to-Revenue Ratio NeuroBo (NRBO)|Price-to-Revenue Ratio SAGE (Sage Therapeutics Inc)|P/S Multiple SNPX (Synaptogenix, Inc.)|Price-to-Revenue Coefficient trevena.com (TRVN)|VIGL - Price-to-Revenue Ratio|WENA (anewmeds.com) - Market Cap to Revenue Ratio|CERE: P/S Multiple
